Status:

COMPLETED

Probiotic BL NCC 2705 and Gluten Sensitivity

Lead Sponsor:

Société des Produits Nestlé (SPN)

Conditions:

Celiac Disease

Non-celiac Gluten Sensitivity

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.

Detailed Description

This trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported Non Coe...

Eligibility Criteria

Inclusion

  • Willing and able to sign written informed consent prior to trial entry
  • Male or female adults \>18 years of age
  • For NCGS: self-reported gluten sensitivity with negative CD serology, on gluten free diet for at least 6 weeks with self-reported significant symptomatic improvement
  • For CD: confirmed serologic and histologic diagnosis of CD and on GFD for at least 12 months with self-reported significant symptomatic improvement
  • Body Mass Index (BMI) within the range \>18 - \<30 kg/m2
  • Willing and able to comply with study procedures and restrictions
  • In good health as determined by a medical history and medical examination

Exclusion

  • Documented IgE-mediated food allergy
  • Subjects following an overly imbalanced or restrictive diet as per nutritional advice
  • Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be detrimental for the participants safety or potentially interfering with the study procedures and/or study outcomes
  • Concurrent organic GI pathology other than benign polyps, diverticulosis, hemorrhoids, lipomas and melanosis coli
  • Previous abdominal surgery with the exception of hernia repair, appendectomy, caesarian section, tubal ligation, hysterectomy, hemorrhoidectomy
  • Patients who received antibiotics in the previous 2 weeks
  • women of childbearing potential not willing to use an effective contraception method

Key Trial Info

Start Date :

October 9 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 15 2020

Estimated Enrollment :

38 Patients enrolled

Trial Details

Trial ID

NCT03775499

Start Date

October 9 2018

End Date

December 15 2020

Last Update

December 23 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Viecuri Hospital

Venlo, Netherlands

Probiotic BL NCC 2705 and Gluten Sensitivity | DecenTrialz